AstraZeneca PLC

Pharmaceuticals

Company Summary

AstraZeneca is a global pharmaceutical company known for its significant contributions to public health, particularly in oncology, respiratory diseases, and its COVID-19 vaccine. The company has made a strong commitment to sustainability, with a target to achieve net-zero emissions by 2050 and a focus on reducing the environmental impact of its operations. AstraZeneca’s ESG rating is driven by its emphasis on health equity and improving access to life-saving medicines globally. However, the company has faced challenges related to drug pricing and affordability in emerging markets, which impact its ESG score. Additionally, while AstraZeneca has made strides in sustainable practices, some environmental groups argue that its carbon reduction efforts are insufficient. For further insights into AstraZeneca’s ESG practices, refer to the latest AstraZeneca ESG report.

ESG Rating Overview

Sustainalytics

Overall ESG Rating :

21.5
Rating Scale
0-10Negligible10-20Low20-30Med30-40High40+Severe
Ranking
Industry Group
Pharmaceuticals110 out of 921
Universe
Global Universe5179 out of 15104

Overall ESG Rating :

95
Rating Scale
0-25Poor 25-50Satisfactory 50-75Good75-100Excellent
0100E92S97G94

Overall ESG Rating :

AA
Rating Scale
CCCB
Laggard
BBBBBA
Average
AAAAA
Leader

AstraZeneca is a leader among 79 companies in the pharmaceuticals industry.

Temperature Rise :

1.3℃
CLIMATE SCALE
≥ 3.85°CLagging > 2°C - < 3.85°CMisaligned ≤ 2°CAligned

News from AstraZeneca PLC

FAQ

What is AstraZeneca's ESG rating?

AstraZeneca holds an ESG rating of 77/100 (according to Sustainalytics), demonstrating its commitment to ethical business practices, social responsibility, and environmental sustainability

How does AstraZeneca approach ESG challenges?

What sustainability efforts is AstraZeneca involved in?